HEALTH PLANS
UNIVERSITY OF UTAH

PRIOR AUTHORIZATION REQUEST FORM
BREYANZI®

For authorization, please answer each question and fax this form PLUS chart notes back to the Advantage U Prior Authorization Department at 801-213-1547.

If you have prior authorization questions, please call Advantage U for assistance: 888-605-0858

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		HCPCS Code:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: ☐ Breyanzi® (lisocabtagene maraleucel)

Dosing/Frequency:____

Questions	Yes	No	Comments/Notes
1. Is the member 18 years of age of older?	☐	☐	
2. Does documentation show the member has relapsed or refractory large B-cell lymphoma, including one of the following: • Diffuse large B-cell lymphoma (DLBCL) not otherwise specified • High-grade B-cell lymphoma • Primary mediastinal large B-cell lymphoma • Follicular lymphoma grade 3B	☐	☐	**Please provide documentation**
3. Does the member have relapsed or refractory disease after at least 2 lines of systemic therapy, which must include both of the following: • Anti-CD20 therapy • Anthracycline containing regimen	☐	☐	**Please provide documentation**
4. Does the member have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1?	☐	☐	**Please provide documentation**
5. Does documentation show an absence of active infection, including Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV), and influenza?	☐	☐	**Please provide documentation**
6. Does the member have any of the following: • CrCl < 30mL/min • ALT > 5 times the upper limit of normal • Left ventricular ejection fraction < 40% • History of chimeric antigen receptor therapy (CAR-T) or other genetically modified T-cell therapy	☐	☐	**Please provide documentation**

7. For sexually active females of reproductive age, does the member have a negative pregnancy test within 1 month of therapy initiation?	☐	☐	**Please provide documentation**
8. Is the member and requesting provider enrolled in the Breyanzi® REMS program?	☐	☐	
9. Does the member have a history of primary central nervous system (CNS) lymphoma or active central nervous system (CNS) involvement by malignancy?	☐	☐	**Please provide documentation**

What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.

Additional information:

Physician Signature:

Policy PHARM-MA-M034
Origination Date: 01/01/2022
Reviewed/Revised Date: 05/18/2022
Next Review Date: 05/18/2023
Current Effective Date: 06/01/2022

Confidentiality Notice
This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.